Furthermore, in the tumor proportion score (TPS: Number of PD-L1 stained tumor cells/Total number of viable tumor cells) ×100) ≥50% subgroup (n = 129), PFS and OS were significantly prolonged through immunotherapy (PFS: HR 0.58, 95% CI, 0.39–0.86, p = 0.003; OS: HR 0.53, 95% CI, 0.35–0.81, p = 0.001). This evidence concerns the gene CD274 and neoplasm.